Optimization in the expression of ASFV proteins for the development of subunit vaccines using poxviruses as delivery vectors

• Published in: Scientific reports Vol. 11; no. 1; pp. 23476 - 12
• Main Authors: Lopera-Madrid, Jaime, Medina-Magües, Lex G., Gladue, Douglas P., Borca, Manuel V., Osorio, Jorge E.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 06.12.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/1647/2300/1514; 692/699/255/2514; African swine fever; African Swine Fever - virology; African Swine Fever Virus - genetics; Animals; Antibodies; Antibodies, Viral - genetics; Antigens; Asfarviridae; Baculoviridae - genetics; Cell Line; Chlorocebus aethiops; DNA vaccines; Domestic animals; Expression vectors; Female; Genomes; Hemorrhage; Hemorrhagic disease; Humanities and Social Sciences; Immunogenicity; Mice; Mice, Inbred BALB C; mRNA; multidisciplinary; p30 Protein; Poxviridae - genetics; Promoter Regions, Genetic - genetics; Science; Science (multidisciplinary); Swine; Vaccines; Vaccines, Attenuated - genetics; Vaccines, Subunit - genetics; Vaccinia; Vero Cells; Viral Proteins - genetics; Viral Vaccines - genetics; Viremia; Virus Replication - genetics
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-02949-x

African swine fever virus (ASFV) causes a highly contagious hemorrhagic disease that affects domestic pig and Eurasian wild boar populations. To date, no safe and efficacious treatment or vaccine against ASF is available. Nevertheless, there are several reports of protection elicited by experimental vaccines based on live attenuated ASFV and some levels of protection and reduced viremia in other approaches such as DNA, adenovirus, baculovirus, and vaccinia-based vaccines. Current ASF subunit vaccine research focuses mainly on delivering protective antigens and antigen discovery within the ASFV genome. However, due to the complex nature of ASFV, expression vectors need to be optimized to improve their immunogenicity. Therefore, in the present study, we constructed several recombinant MVA vectors to evaluate the efficiency of different promoters and secretory signal sequences in the expression and immunogenicity of the p30 protein from ASFV. Overall, the natural poxvirus PrMVA13.5L promoter induced high levels of both p30 mRNA and specific anti-p30 antibodies in mice. In contrast, the synthetic PrS5E promoter and the S E/L promoter linked to a secretory signal showed lower mRNA levels and antibodies. These findings indicate that promoter selection may be as crucial as the antigen used to develop ASFV subunit vaccines using MVA as the delivery vector.